GE Healthcare has announced the inauguration of an open-access lab at the Mereside Campus of Alderley Park in the United Kingdom, which will be used to support acceleration of biotech, health, and life-sciences research.
GE Healthcare has announced the inauguration of an open-access lab at the Mereside Campus of Alderley Park in the United Kingdom, which will be used to support acceleration of biotech, health, and life-sciences research.
According to an Oct. 23, 2019 press release, the new lab will feature advanced protein and cell analysis technologies to support small and medium-sized enterprises (SMEs) from early stage R&D to process development through to manufacturing. Additionally, it is hoped that valuable insights into the challenges faced by SMEs will be gained from the experiences with the open-access lab, allowing for the development of solutions that could benefit the whole life-sciences community in the UK.
“We’re thrilled to be launching this facility which will help accelerate our customers’ research and discovery aims,” said Kath Mackay, managing director, Alderley Park, in the press release. “The new GE laboratory is an excellent addition to the highly specialized scientific services offered at the Park and complements the existing oncology, analytical, and open access services.”
Conor McKechnie, chief marketing officer, GE Healthcare Life Sciences, added, “The start-up community at Alderley Park has the creativity, vision, and scientific expertise to help transform medicine. Providing them access to our technologies and services is a natural part of our mission to accelerate and advance biotherapeutics.”
“GE Healthcare Life Sciences is an important partner for the BioIndustry Association (BIA) and our community,” stated Steve Bates OBE, chief executive of the BIA. “This new lab will give our members early access and training for all the tools they need for drug discovery, protein science, and bioprocessing research.”
Source: GE Healthcare
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.